

Date: 14th August, 2025

To
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Scrip Code: 542248

Subject: Outcome of Board Meeting held on today i.e. 14th August, 2025 in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam

With reference to our Intimation vide letter dated Friday, 08th August 2025 we wish to inform you that the Board Directors of the Company in its meeting held today i.e. Thursday, 14th August 2025 through Video Conferencing have Inter-alia;

1. Considered and Approved the Standalone Unaudited Financial Results of the Company for the quarter ended 30th June, 2025 along with the Limited Review Report.
2. Considered and Approved the Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June, 2025 along with the Limited Review Report.
3. Mr. Mohak Gupta, Director of the company is authorized to sign the financial Result for the quarter ended 30th June, 2025.

Further the said outcome shall be uploaded on the website of the company at www.deccanhealthcare.co.in.

Details as required under regulation 30 of listing regulations read with SEBI circular SEBI/HO/CFD/CFDPoD 1/P/CIR/2023/123 dated July 13, 2023 are provided herewith.

The meeting was commenced at 03:30 P.M. and concluded at 03:40 P.M.

You are requested to take the information on record and oblige.

Thanking You,
Yours faithfully

For Deccan Health Care Limited

Ronak Darji
Company Secretary & Compliance Officer
(M. No. A67434)

Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in



Date: 14th August, 2025

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001, Maharashtra

Stock Code: 542248

Subject: Submission of Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2025 along with Limited Review Reports issued by Statutory Auditors

Dear Sir/Madam

With reference to above captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2025 along with the Limited Review Report issued by Statutory Auditors.

The said financial results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

We request you to take the same on records.

Thanking You,
Yours Faithfully,
For and on behalf of
Deccan Health Care Limited

Ronak Darji
Company Secretary & Compliance Officer
(M. No. A67434)
Encl: a/a

Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in



Limited Review Report on unaudited standalone financial results of Deccan Health Care Limited for the Quarter ended 30th June, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors Of,
Deccan Health Care Limited

We have reviewed the accompanying the statement of unaudited Standalone financial results ("the financial statement") of **Deccan Health Care Limited** ("the Company") for the Quarter ended on **30th June, 2025**. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down as per accounting standard prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results, prepared in accordance with applicable Indian Accounting standards ("Ind AS") and other recognized accounting practices and policies as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in india, has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Associates
Chartered Accountants
F.R.No. 333288W

Akhlaq Ahmad Mutvalli
Partner

M. No. 181329

UDIN: - 25181329BMHBXY7410



Date: - 14th August, 2025
Place: - Ahmedabad




DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

StoyWoW 6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Somajiguda, Hyderabad, Nampally, Telangana, India, 500082

Standalone financial Results for the Quarter Ended on 30th June, 2025

Sl. No.	Particulars	Rs. in Lakhs (unless otherwise stated)			
		Quarter Ended		Year End	
		30th June, 2025	31st March, 2025	30th June, 2024	31st March, 2025
		Unaudited	Audited	Unaudited	Audited
	Income from Operations				
	a) Revenue from operations	2,146.95	2,082.12	1,506.11	7,513.19
	b) Other income	0.62	0.46	-	0.57
	Total Income	2,147.57	2,082.58	1,506.11	7,513.76
II	Expenses				
	a) Cost of materials consumed	1,905.21	1,181.86	629.78	4,096.37
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(361.27)	227.69	245.29	660.78
	c) Employee Benefit Expenses	136.37	111.61	90.84	434.82
	d) Finance costs	1.71	1.50	1.65	7.39
	e) Depreciation and amortization expense	40.55	35.95	36.02	145.26
	f) Other Expenses	394.89	499.25	453.24	2,002.22
	Total Expenses	2,117.46	2,057.86	1,456.82	7,346.84
III	Profit Before Tax (PBT) (I-II)	30.11	24.72	49.29	166.92
IV	Tax Expense				
	a) Current tax	13.17	10.44	15.87	57.01
	b) Deferred tax (Liability) / Assets	(4.31)	0.68	(3.47)	(9.88)
	Total Tax Expenses	8.86	11.12	12.40	47.13
V	Profit After Tax (PAT) (III-IV)	21.25	13.60	36.89	119.79
VI	Other Comprehensive Income / (Expense)				
	Items that will not be reclassified to profit & loss (net of tax)	3.80	15.28	(0.01)	15.22
	Items that will be reclassified to profit & loss (net of tax)	-	-	-	-
	Total Other Comprehensive Income	3.80	15.28	(0.01)	15.22
VII	Total Comprehensive Income for the Year (V+VI)	25.05	28.88	36.88	135.01
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,474.92	2,342.55	2,037.62	2,342.55
IX	Other Equity				8,312.66
X	Earnings Per Equity Share- Basic/Diluted				
	Basic	0.09	0.06	0.18	0.56
	Diluted	0.09	0.05	0.14	0.47



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Somajiguda, Hyderabad, Nampally, Telangana, India, 500082

Notes to Accounts -Standalone Financial Statements-

[1] The above Unaudited Standalone Financial Results of Deccan Health Care Limited for the Quarter Ended on 30th June, 2025 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 14th August, 2025. These results have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (LODR) (as amended).

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as amended] prescribed under section 133 of the companies act, 2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] The figure for the quarter ended 31st March, 2025 are balancing figures between the audited figures in respect of year ended on 31st March, 2025 and the nine month ended figures upto the third quarter ended on 31st December '24.

[6] During the quarter ended June 2025, the Company received Rs. 136.95 lakhs and In the Previous Quarter Rs 160.88 Lakhs from warrant holders. Of this amount, the Company issued and allotted 13,23,667 equity shares upon receipt of the full consideration for the respective share warrants.

Rs. 75.00 lakhs. received towards Initial Consideration equivalent to 25% of the total consideration received against the 10,00,000 Warrant issue at Price fixed of Rs. 30 per Warrant in terms of the SEBI ICDR Regulations has been forfeited by the Company due to non-exercise of option of conversion attached to such warrant within Warrant Exercise Period of 18 months. The Warrants are lapsed and the amount received stand forfeited by the Company.


[7] Out of Rs. 297.83 lakhs Received from the warrant holders, During the Current Quarter all has been utilized in accordance with the approved objectives associated with the conversion of the warrants.


[8] The Status of investor's complaints during the quarter ended on 30th June, 2025 as under:-

Complaints pending at the beginning of the period	NIL
Complaints received during the period	NIL
Complaints disposed during the period	NIL
Complaints resolved at the end of the period	NIL

Date : 14th August, 2025
Place :- Hyderabad

For, Deccan Health Care Limited


Mohak Gupta
Director
DIN - 03534904





Independent Auditor's Limited Review Report on the Quarterly Unaudited Consolidated Financial Results of the Deccan Health Care Limited, for the Quarter ended 30th June, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Unaudited Financial Results of **Deccan Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter ended **30th June, 2025** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



The Statement includes the results of the following entities:

List of Subsidiaries:

1. Beyoung Store Private Limited

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the statement provided by the Management related to subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes the unaudited interim financial results/ financial information in respect of:

- a) 1 subsidiary, whose unaudited interim financial results reflect total income of Rs. 99.32 Lakhs, total profit after tax of Rs. 2.46 Lakhs and total comprehensive income of Rs. 2.46 Lakhs for the quarter ended 30th June, 2025, as considered in the Statement.


These interim financial results have been approved and furnished to us by the Management, and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited interim financial result.

Our conclusion on the statement is not modified in respect of these matters

For, Keyur Shah & Associates

Chartered Accountants

F.R.No. 333288W



Akhlaq Ahmad Mutvalli

Partner

M. No. 181329

UDIN: - 25181329BMHBXZ8396

Date: - 14th August, 2025

Place: - Ahmedabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Consolidated financial Results for the Quarter ended on 30th June '25

Sr. No.	Particulars	Amounts in Lakhs (unless otherwise stated)			
		Quarter Ended		Year ends.	
		30th June '25	31st March '25	30th June '24	31st March '25
		Unaudited	Audited	Unaudited	Audited
i	Income From Operations				
	a) Revenue from Operations	2,214.02	2,074.72	1,506.11	7,505.79
	b) Other Income	0.62	0.46	-	0.57
	Total Income	2,214.64	2,075.18	1,506.11	7,506.36
II	Expenses				
	a) Cost of Materials Consumed	1,911.56	1,174.46	629.78	4,088.97
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(361.27)	227.69	245.29	660.78
	c) Employee Benefit Expense	138.68	113.91	93.28	444.21
	d) Finance Costs	1.72	1.51	1.65	7.42
	e) Depreciation and Amortisation Expense	40.55	35.95	36.02	145.26
	f) Other Expenses	450.01	498.17	451.45	1,996.70
	Total Expenses	2,181.25	2,051.69	1,457.47	7,343.34
III	Profit/ (Loss) Before Tax (I-II)	33.39	23.49	48.64	163.02
IV	Tax Expense				
	a) Current Tax	13.99	10.44	15.87	57.01
	b) Deferred Tax (Asset)/Liabilities	(4.31)	0.70	(3.47)	(9.86)
	Total Tax Expense	9.68	11.14	12.40	47.15
V	Net Profit/ (Loss) After Tax for the Period (III-IV)	23.71	12.35	36.24	115.87
VI	Other Comprehensive Income/ (Loss)				
	a) Items that will not be reclassified to Profit & Loss income tax in respect of above	5.08	20.42	(0.01)	20.34
	b) Items that may be reclassified to Profit & Loss Income tax in respect of above	(1.28)	(5.14)	0.00	(5.12)
	Total Other Comprehensive Income/ (Loss)	3.80	15.28	(0.01)	15.22
VII	Total Comprehensive Income/ (Loss) for the period (V + VI)	27.51	27.63	36.23	131.09
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,474.92	2,342.55	2,037.62	2,342.55
IX	Other Equity				
X	Earnings Per Equity Share- Basic/Diluted				8,296.52
	Basic	0.10	0.05	0.18	0.54
	Diluted (After Conversion of warrants)	0.10	0.05	0.14	0.45



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Notes to Accounts - Consolidated Financial Statement

[1] The above unaudited consolidated financial results for the quarter ended 30th June, 25 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 14th August, 2025. A Limited Review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as amended] prescribed under section 133 of the companies act, 2013.

[4] The figure for the quarter ended 31st March '25 are balancing figures between the audited figures in respect of year ended on 31st March '25 and the nine month ended figures upto the third quarter ended on 31st December '24.

[5] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[6] During the quarter ended June 2025, the Company received Rs. 136.95 lakhs and In the Previous Quarter Rs 160.88 Lakhs from warrant holders. Of this amount, the Company issued and allotted 13,23,667 equity shares upon receipt of the full consideration for the respective share warrants.

Rs. 75.00 lakhs, received towards Initial Consideration equivalent to 25% of the total consideration received against the 10,00,000 Warrant Issue at Price fixed of Rs. 30 per Warrant in terms of the SEBI ICDR Regulations has been forfeited by the Company due to non-exercise of option of conversion attached to such warrant within Warrant Exercise Period of 18 months. The Warrants are lapsed and the amount received stand forfeited by the Company.

[7] Out of Rs. 297.83 lakhs Received from the warrant holders, During the Current Quarter all has been utilized in accordance with the approved objectives associated with the conversion of the warrants.

[8] The Status of investor's complaints during the quarter ended on 30th June '25 are as under:-

Complaints pending at the beginning of the period	NIL
Complaints received during the period	NIL
Complaints disposed during the period	NIL
Complaints resolved at the end of the period	NIL

Date : 14th August, 2025
Place : Hyderabad

For, Deccan Health Care Limited


Mohak Gupta
Director
DIN - 03534904

